A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

Promrat, Kittichai, Lutchman, Glen, Uwaifo, Gabriel I., Freedman, Renee J., Soza, Alejandro, Heller, Theo, Doo, Edward, Ghany, Marc, Premkumar, Ahalya, Park, Yoon, Liang, Jake T., Yanovski, Jack A., Kleiner, David E., Hoofnagle, Jay H.·2004·Hepatology

DOI 10.1002/hep.20012

Cited by (721)

Items 201–300 of 721

Nonalcoholic fatty liver disease: from pathogenesis to patient care
Gabriel Perlemuter, Amélie Bigorgne, Anne‐Marie Cassard, Sylvie Naveau · 2007 · Nature Clinical Practice Endocrinology & Metabolism
Evaluation and management of obesity-related nonalcoholic fatty liver disease
Clare Nugent, Zobair M. Younossi · 2007 · Nature Clinical Practice Gastroenterology & Hepatology
Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)
Harrison, Stephen A., Thang, Carole, Bolze, Sébastien, Dewitt, Sheila, Hallakou-Bozec, Sophie, Dubourg, Julie, Bedossa, Pierre, Cusi, Kenneth, Ratziu, Vlad, Grouin, Jean-Marie et al. · 2023 · Journal of Hepatology
A high‐fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non‐alcoholic steatohepatitis in mice
Norihiro Kubota, Shoichi Kado, Mitsuyoshi KANO, Norie Masuoka, Yuriko Nagata, Toshihide Kobayashi, Kouji Miyazaki, Fumiyasu Ishikawa · 2013 · Clinical and Experimental Pharmacology and Physiology
Endocrine causes of nonalcoholic fatty liver disease
Laura Marino · 2015 · World Journal of Gastroenterology
Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease
William Nseir, Adel Shalata, Alon T Marmor, Nimer Assy · 2011 · Digestive Diseases and Sciences
Clinical presentation and treatment of type 2 diabetes in children
Orit Pinhas‐Hamiel, Philip Scott Zeitler · 2007 · Pediatric Diabetes
Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement
Glen A. Lutchman, Kittichai Promrat, David Erwin Kleiner, Theo Heller, Marc G. Ghany, Jack Adam Yanovski, T. Jake Liang, Jay H. Hoofnagle · 2006 · Clinical Gastroenterology and Hepatology
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
John G. McHutchison, Zachary D Goodman, Keyur Patel, Hala R. Makhlouf, Maribel Rodriguez‐Torres, Mitchell L. Shiffman, Don C. Rockey, Petr Husa, Wan‐Long Chuang, Robert A. Levine et al. · 2009 · Gastroenterology
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko, Yoshio Sumida, Saiyu Tanaka, Kojiroh Mori, Hiroyoshi Taketani, Hiroshi Ishiba, Tasuku Hara, Akira Okajima, Atsushi Umemura, Taichiro Nishikawa et al. · 2016 · Hepatology Research
Non‐alcoholic steatohepatitis in children
Nanda N. Kerkar · 2004 · Pediatric Transplantation
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
Bogdan Balas, Renata Belfort, Stephen A. Harrison, Celia Darland, Joan Finch, Steven Schenker, Amalia Gastaldelli, Kenneth J. Cusi · 2007 · Journal of Hepatology
Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside
Feng Zhang, Desong Kong, Yin Lu, Shizhong Zheng · 2012 · Cellular and Molecular Life Sciences
Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management
Piero Portincasa, Ignazio Grattagliano, Vincenzo Ostilio Palmieri, Giuseppe Palasciano · 2004 · Clinical Biochemistry
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
Takumi Hirata, Kengo Tomita, Toshihide Kawai, Hirokazu Yokoyama, Akira Shimada, Masahiro Kikuchi, Hiroshi Hirose, Hirotoshi Ebinuma, Junichiro Irie, Keisuke Ojiro et al. · 2013 · International Journal of Endocrinology
Nonalcoholic Fatty Liver Disease
Chandana G. Lall, Alex M. Aisen, Navin Bansal, Kumaresan Sandrasegaran · 2008 · American Journal of Roentgenology
Diabetes medications and risk of HCC
Plaz Torres, Maria Corina, Jaffe, Ariel, Perry, Rachel, Marabotto, Elisa, Strazzabosco, Mario, Giannini, Edoardo G. · 2022 · Hepatology
The metabolic syndrome and nonalcoholic fatty liver disease in children
Shikha S. Sundaram, Philip Scott Zeitler, Kristen J. Nadeau · 2009 · Current Opinion in Pediatrics
Sphingolipid metabolism in non-alcoholic fatty liver diseases
Marion Régnier, Arnaud Polizzi, Hervé Guillou, Nicolas Loiseau · 2018 · Biochimie
Current treatment of non‐alcoholic fatty liver disease
Mohamed Hassan Ahmed, Christopher D. Byrne · 2008 · Diabetes Obesity and Metabolism
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
Lance L. Stein, Mamie H. Dong, Rohit Seth Loomba · 2009 · Advances in Therapy
Should Nonalcoholic Fatty Liver Disease Be Renamed?
Paola Loria, Amedeo Lonardo, Nicola Carulli · 2005 · Digestive Diseases
Is Adiponectin Involved in the Pathogenesis of Nonalcoholic Steatohepatitis?
Raj Vuppalanchi, Smitha Marri, Dhanashri Kolwankar, Robert V. Considine, Naga Chalasani · 2005 · Journal of Clinical Gastroenterology
Therapy of nonalcoholic fatty liver disease: current status.
Marko Duvnjak, Vedran Tomašić, Marija Gomerčić, Lea Smircic Duvnjak, Neven Baršić, Ivan Lerotić · 2009 · PubMed
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy
M.A. Karsdal, Kim Henriksen, Mette Juul Nielsen, I. Byrjalsen, Diana Julie Leeming, Stephen D. Gardner, Zachary D Goodman, Keyur Patel, Aleksander Ahm Krag, Claus Christiansen et al. · 2016 · American Journal of Physiology-Gastrointestinal and Liver Physiology
T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease
Lucia Pacifico · 2011 · World Journal of Gastroenterology
A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis
Jill K. J. Gaidos, Bruce E. Hillner, Arun Jayant Sanyal · 2008 · Liver International
Non-alcoholic steatohepatitis
Peter L. M. Jansen · 2004 · European Journal of Gastroenterology & Hepatology
Non-alcoholic fatty liver disease and insulin resistance
Mariana Verdelho Machado, Helena Cortez‐Pinto · 2005 · European Journal of Gastroenterology & Hepatology
Liver-Specific Peroxisome Proliferator–Activated Receptor α Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan
Markus Clemenz, Nikolaj Frost, Michael Schupp, Sandrine Caron, Anna Foryst‐Ludwig, Christian Böhm, Martin Hartge, Ronald Gust, Bart Staels, Thomas Unger et al. · 2008 · Diabetes
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease
Raffaele Galiero, Alfredo Caturano, Erica Vetrano, Arturo Cesaro, Luca Rinaldi, Teresa Salvatore, Raffaele Marfella, Celestino Sardu, Elisabetta Moscarella, Felice Gragnano et al. · 2021 · Reviews in Cardiovascular Medicine
Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis
Maria Luisa Balmer, Kathrin Siegrist, Arthur Zimmermann, Jean‐François Dufour · 2009 · Liver International
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway
CLAUDIA M. FILOZOF, Barry J. Goldstein, Richard N. Williams, Arun Jayant Sanyal · 2015 · Drugs
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
Stefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, Enrica Baldelli, Amedeo Lonardo · 2016 · Advances in Therapy
Activation of Peroxisome Proliferator-Activated Receptor Gamma by Rosiglitazone Increases Sirt6 Expression and Ameliorates Hepatic Steatosis in Rats
Soo Jin Yang, Jung Mook Choi, Seoung Wan Chae, Won Jun Kim, Se Eun Park, Eun‐Jung Rhee, Won‐Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim et al. · 2011 · PLoS ONE
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
Lisa B. VanWagner, Mary Eugenia Rinella · 2011 · Therapeutic Advances in Gastroenterology
Therapeutic Trials in Nonalcoholic Steatohepatitis
Vlad Ratziu, Stephen Hugh Caldwell, Brent A. Neuschwander‐Tetri · 2010 · Hepatology
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Zeynel Abidin Öztürk · 2014 · World Journal of Hepatology
Examining the safety of PPAR agonists – current trends and future prospects
Michele Bortolini, Matthew B. Wright, Martin Bopst, Bogdana Ioana Balas · 2012 · Expert Opinion on Drug Safety
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Hyejin Yoon · 2014 · World Journal of Hepatology
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease
Won Kyum Kim, B. G. Kim, J. S. Lee, C. K. Lee, Jong Eun Yeon, M. S. Chang, J. H. Kim, H. Kim, S. Yi, J. Lee et al. · 2017 · Alimentary Pharmacology & Therapeutics
Hepatic Complications of Obesity
Anna Mae Diehl · 2010 · Gastroenterology Clinics of North America
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
D Shyangdan, Christine Clar, Nazim Ghouri, R Henderson, Tul Maya Gurung, David Preiss, Naveed A. Sattar, Abigail Fraser, Norman R Waugh · 2011 · Health Technology Assessment
How should we manage patients with non‐alcoholic fatty liver disease in 2007?
Henry Lik‐Yuen Chan, H Janaka de Silva, Nancy W.Y. Leung, Seng Gee Lim, Geoffrey C. Farrell, the Asia–Pacific Working Party on NAFLD · 2007 · Journal of Gastroenterology and Hepatology
Thiazolidinediones and their Fluid-Related Adverse Effects
Janaka J. Karalliedde, Robin E. Buckingham · 2007 · Drug Safety
Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol
Jennifer E. Lambert, Jill A. Parnell, Bertus Eksteen, Maitreyi Raman, Marc R. Bomhof, Kevin P. Rioux, Karen L. Madsen, Raylene A. Reimer · 2015 · BMC Gastroenterology
Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability
Vlad Ratziu, Elisabetta Bugianesi, John B. Dixon, E Fassio, Mattias Ekstedt, Frédéric Charlotte, Stergios Kechagias, Thierry Poynard, Rolf Olsson · 2007 · Alimentary Pharmacology & Therapeutics
Nonalcoholic fatty liver disease as a component of the metabolic syndrome
Mouen A. Khashab, Suthat Liangpunsakul, Naga Chalasani · 2008 · Current Gastroenterology Reports
Hypertension and fatty liver: guilty by association?
Matthew Brookes, Brian T. Cooper · 2007 · Journal of Human Hypertension
Novel Anti-fibrotic Therapies
Benita L. McVicker, Robert G. Bennett · 2017 · Frontiers in Pharmacology
Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map
Jai Kumar, Roha Saeed Memon, Izza Shahid, Tehlil Rizwan, Maryam Zaman, Ritesh George Menezes, Sarwan Kumar, Tariq Jamal Siddiqi, Muhammad Usman · 2020 · Digestive and Liver Disease
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions
Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny, Ebtehal El‐Demerdash · 2021 · Life Sciences
Nonalcoholic Fatty Liver Disease
Angelo H. Paredes, Dawn McDowell Torres, Stephen A. Harrison · 2012 · Clinics in Liver Disease
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung‐Soo Kim, Byung‐Wan Lee · 2020 · Clinical and Molecular Hepatology
Which CIDE are you on? Apoptosis and energy metabolism
Tomo Yonezawa, Riho Kurata, Minoru Kimura, Hidetoshi Inoko · 2010 · Molecular BioSystems
Nonalcoholic Fatty Liver Disease and Obesity
Sherif N. Saadeh · 2007 · Nutrition in Clinical Practice
Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease
Emad A. Rakha, Louise M. Adamson, Emily Bell, Keith R Neal, Stephen D. Ryder, Philip Kaye, Guruprasad Padur Aithal · 2010 · Journal of Clinical Pathology
Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels
Promrat, Kittichai, Longato, Lisa, Wands, Jack R., de la Monte, Suzanne M. · 2011 · Hepatology Research
Review article: the metabolic syndrome and non‐alcoholic fatty liver disease
P. LORIA, Amedeo Lonardo, Lucia Carulli, A. M. VERRONE, Matteo Ricchi, S. Lombardini, A Rudilosso, Stefano Ballestri, Nicola Carulli · 2005 · Alimentary Pharmacology & Therapeutics
Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?
Amedeo Lonardo, Stefano Bellentani, Vlad Ratziu, Paola Loria · 2011 · Expert Review of Gastroenterology & Hepatology
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Juan Pablo Arab · 2014 · World Journal of Gastroenterology
Pathological features of NASH.
Elizabeth M Brunt, Dina G Tiniakos · 2005 · PubMed
Pleiotropic effects of thiazolidinediones
Christos V. Rizos, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Moses Elisaf · 2008 · Expert Opinion on Pharmacotherapy
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
Detlef Schuppan, Mark D. Gorrell, Thomas Klein, Michael Mark, Nezam H. Afdhal · 2009 · Liver International
Review article: drug therapy for non‐alcoholic fatty liver disease
Kevin M. Comar, Richard K. Sterling · 2005 · Alimentary Pharmacology & Therapeutics
Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management
Nila Rafiq, Zobair M. Younossi · 2009 · Clinics in Liver Disease
Treatment strategies in nonalcoholic fatty liver disease
Herbert Tilg, Arthur Kaser · 2005 · Nature Clinical Practice Gastroenterology & Hepatology
Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection
Robin E. Buckingham · 2005 · Hepatology Research
Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis
Partha Pratim Das, Subhash Medhi · 2023 · Cytokine
Rosiglitazone Aggravates Nonalcoholic Fatty Pancreatic Disease in C57BL/6 Mice Fed High-Fat and High-Sucrose Diet
Caroline Fernandes‐Santos, Rafael Evangelista Carneiro, Leonardo de Souza Mendonça, Márcia Barbosa Águila, Carlos Alberto Mandarim‐de‐Lacerda · 2009 · Pancreas
The Relevance of Liver Histology to Predicting Clinically Meaningful Outcomes in Nonalcoholic Steatohepatitis
Mangesh R. Pagadala, Arthur J. McCullough · 2012 · Clinics in Liver Disease
Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease
Nikolaos Gatselis, George Ntaios, Konstantinos P. Makaritsis, George Ν. Dalekos · 2013 · Clinical and Experimental Medicine
Role of mitochondria and mitochondria‐targeted agents in non‐alcoholic fatty liver disease
Thekkuttuparambil Ananthanarayanan Ajith · 2017 · Clinical and Experimental Pharmacology and Physiology
Pharmacological agents for NASH
Vlad Ratziu · 2013 · Nature Reviews Gastroenterology & Hepatology
The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial
Mohsen Razavizade, Raika Jamali, Abbas Arj, Sayyed Mohammad Matini, Alireza Moraveji, Effat Taherkhani · 2013 · Hepatitis Monthly
Thiazolidinediones and the liver in humans
Hannele Yki‐Järvinen · 2009 · Current Opinion in Lipidology
Deletion of angiotensin II type I receptor reduces hepatic steatosis
Yoshitaka Nabeshima, Susumu Tazuma, Keishi Kanno, Hideyuki Hyogo, Kazuaki Chayama · 2009 · Journal of Hepatology
Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies
E Fassio, Estela Álvarez, Nora Domínguez, Graciela Landeira, Cristina Longo · 2004 · Hepatology
Diagnostic Value of Ultrasonographic Examination for Nonalcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery
Ren-Jow Liang, Hsih-Hsi Wang, Wei-Jei Lee, Phui-Ly Liew, Jaw-Town Lin, Ming-Shiang Wu · 2007 · Obesity Surgery
Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology
Yoshihisa Takahashi · 2010 · World Journal of Gastroenterology
Thiazolidinediones for nonalcoholic steatohepatitis
Lingling He, Xiaoli Liu, Lijia Wang, Zhiyun Yang · 2016 · Medicine
Nonalcoholic steatohepatitis
Brian P. Mulhall, Zobair M. Younossi · 2004 · Current Treatment Options in Gastroenterology
Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes
Ildiko Lingvay, Philip Raskin, Lidia S. Szczepaniak · 2007 · Journal of Diabetes and its Complications
Herbal medicines for fatty liver diseases
Zhaolan Liu, Jiang Zhu, Yanan Wu, Xi'e Zhuang, Jianping Liu · 2011 · Cochrane Database of Systematic Reviews
Evolving aspects of liver transplantation for nonalcoholic steatohepatitis
Michael Charlton · 2013 · Current Opinion in Organ Transplantation
Current treatment options for the metabolic syndrome
PRAKASH C. DEEDWANIA, Н. И. Волкова · 2005 · Current Treatment Options in Cardiovascular Medicine
Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
Elisabetta Bugianesi, Rebecca Marzocchi, Nicola Villanova, Giulio Marchesini · 2004 · Best Practice & Research Clinical Gastroenterology
Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin‐sensitizing agents
P. D. Home, Giovanni Pacini · 2007 · Diabetes Obesity and Metabolism
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome
Warshauer, Jeremy T., Lopez, Ximena, Gordillo, Ruth, Hicks, Jessica, Holland, William L., Anuwe, Estelle, Blankfard, Martin B., Scherer, Philipp E., Lingvay, Ildiko · 2015 · Diabetes/Metabolism Research and Reviews
Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead
Runping Liu, Yajing Li, Qi Zheng, Mingning Ding, Huiping Zhou, Xiaojiaoyang Li · 2023 · Acta Pharmaceutica Sinica B
Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet
Heriberto Rodríguez-Hernández, Miriam Cervantes-Huerta, Martha Rodríguez Morán, Fernando Guerrero‐Romero · 2011 · Annals of Hepatology
The safety of thiazolidinediones
Keith G. Tolman · 2011 · Expert Opinion on Drug Safety
Relationship of Liver Enzymes to Insulin Sensitivity and Intra-Abdominal Fat
Tara M Wallace, Kristina M. Utzschneider, Jenny Tong, Darcy B. Carr, Sakeneh Zraika, Daniel D. Bankson, Robert H. Knopp, Steven E. Kahn · 2007 · Diabetes Care
Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression
Mattias Ekstedt, Lennart Franzén, Ulrik Mathiesen, Stergios Kechagias · 2011 · Scandinavian Journal of Gastroenterology
Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas
Yao-Chi Liu · 2006 · World Journal of Gastroenterology
Reversal of Fibrosis: No Longer a Pipe Dream?
Jonathan Andrew Fallowfield, Timothy James Kendall, John Peter Iredale · 2006 · Clinics in Liver Disease
Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan
Ryuzo Kawamori, Takashi Kadowaki, Morikazu Onji, Yutaka Seino, Yasuo Akanuma · 2006 · Diabetes Research and Clinical Practice
The peroxisome proliferator-activated receptor-γ agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, -amino acid-defined diet
Hirofumi Uto, Chihiro Nakanishi, A. Ido, Satoru Hasuike, Kazunori Kusumoto, Hirohiko ABE, Masatsugu Numata, K NAGATA, Katsuhiro Hayashi, H Tsubouchi · 2005 · Hepatology Research
Pharmacotherapy for alcoholic patients with alcoholic liver disease
Vuittonet, Cynthia L., Halse, Michael, Leggio, Lorenzo, Fricchione, Samuel B., Brickley, Michael, Haass-Koffler, Carolina L., Tavares, Tonya, Swift, Robert M., Kenna, George A. · 2014 · American Journal of Health-System Pharmacy
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Eugene Chang, Cheol‐Young Park, Sung Woo Park · 2013 · Journal of Diabetes Investigation